内容紹介
Summary
Aim: Low serum carnitine levels have been reported in patients with cancer receiving chemotherapy and are considered one of the factors causing fatigue associated with chemotherapy. We evaluated the effectiveness of L-carnitine in the treatment of fatigue associated with chemotherapy in patients with gastric cancer(GC). Materials and methods: We performed a randomized controlled trial between December 2013 and December 2018. Untreated patients with advanced GC were included in the study; 1 patient developed an allergy after receiving the first chemotherapy and was excluded from the study. The primary endpoint was brief fatigue inventory(BFI). Patients were categorized into 2 groups: those who received L-carnitine oral supplements(group C)and those who did not receive L-carnitine oral supplements(group N). Results: The serum carnitine levels were improved significantly in group C compared with group N. BFI was more aggravated in group N than group C; however, the difference was not significant. Conclusion: We could not demonstrate the effectiveness of L-carnitine in the treatment of fatigue associated with chemotherapy in patients with GC.
要旨
目的: 癌患者において抗癌剤の影響による体内カルニチン濃度の低下が報告され,倦怠感の要因の一つと考えられている。今回,進行胃癌の化学療法に伴う倦怠感に対するL-カルニチンの有用性を検証した。対象・方法: 2013年12月～2018年12月に化学療法施行予定の未治療進行胃癌17例を登録し,前向きのランダム化比較試験を行った(UMIN000012141)。1例は初回化学療法のアレルギーのため中止した。主要評価項目はBrief Fatigue Inventory(BFI)とし,L-カルニチン投与群(C群7例)と無治療群(N群9例)で比較検討した。結果: 血中カルニチン濃度はC群で有意に上昇を認めた。BFIはN群でC群に比べて上昇傾向を認めたが,群間差は認めなかった。結語: 胃癌患者の化学療法に伴う倦怠感に対するL-カルニチンの投与は,倦怠感の改善における有用性を得られなかった。
目次
Aim: Low serum carnitine levels have been reported in patients with cancer receiving chemotherapy and are considered one of the factors causing fatigue associated with chemotherapy. We evaluated the effectiveness of L-carnitine in the treatment of fatigue associated with chemotherapy in patients with gastric cancer(GC). Materials and methods: We performed a randomized controlled trial between December 2013 and December 2018. Untreated patients with advanced GC were included in the study; 1 patient developed an allergy after receiving the first chemotherapy and was excluded from the study. The primary endpoint was brief fatigue inventory(BFI). Patients were categorized into 2 groups: those who received L-carnitine oral supplements(group C)and those who did not receive L-carnitine oral supplements(group N). Results: The serum carnitine levels were improved significantly in group C compared with group N. BFI was more aggravated in group N than group C; however, the difference was not significant. Conclusion: We could not demonstrate the effectiveness of L-carnitine in the treatment of fatigue associated with chemotherapy in patients with GC.
要旨
目的: 癌患者において抗癌剤の影響による体内カルニチン濃度の低下が報告され,倦怠感の要因の一つと考えられている。今回,進行胃癌の化学療法に伴う倦怠感に対するL-カルニチンの有用性を検証した。対象・方法: 2013年12月～2018年12月に化学療法施行予定の未治療進行胃癌17例を登録し,前向きのランダム化比較試験を行った(UMIN000012141)。1例は初回化学療法のアレルギーのため中止した。主要評価項目はBrief Fatigue Inventory(BFI)とし,L-カルニチン投与群(C群7例)と無治療群(N群9例)で比較検討した。結果: 血中カルニチン濃度はC群で有意に上昇を認めた。BFIはN群でC群に比べて上昇傾向を認めたが,群間差は認めなかった。結語: 胃癌患者の化学療法に伴う倦怠感に対するL-カルニチンの投与は,倦怠感の改善における有用性を得られなかった。